3 Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio
https://www.zacks.com/stock/news/2194242/3-reasons-to-retain-amn-healthcare-amn-stock-in-your-portfolio?cid=CS-ZC-FT-analyst_blog|rank_focused-2194242
Dec 06, 2023 - Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
0
Why You Should Retain Merit Medical (MMSI) Stock for Now
https://www.zacks.com/stock/news/2196236/why-you-should-retain-merit-medical-mmsi-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2196236
Dec 11, 2023 - Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
0
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
https://www.zacks.com/stock/news/2196894/here-s-why-you-should-retain-surmodics-srdx-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2196894
Dec 12, 2023 - Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
0
Here's Why You Should Retain Catalent (CTLT) Stock for Now
https://www.zacks.com/stock/news/2198761/here-s-why-you-should-retain-catalent-ctlt-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2198761
Dec 15, 2023 - Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.
0
DexCom's (DXCM) G7 CGM Connects With Tandem's Insulin Pump
https://www.zacks.com/stock/news/2200159/dexcom-s-dxcm-g7-cgm-connects-with-tandem-s-insulin-pump?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200159
Dec 19, 2023 - Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.
0
Masimo's (MASI) Stork Baby Monitoring System Approved by FDA
https://www.zacks.com/stock/news/2200083/masimo-s-masi-stork-baby-monitoring-system-approved-by-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200083
Dec 19, 2023 - The latest FDA clearance of Masimo's (MASI) Stork smart home baby monitoring system is likely to provide a continuous and accurate view of babies' health data.
0
Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment
https://www.zacks.com/stock/news/2200160/glaukos-gkos-idose-tr-gets-fda-nod-for-glaucoma-treatment?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200160
Dec 19, 2023 - The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.
0
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
https://www.zacks.com/stock/news/2200712/reasons-to-retain-fresenius-medical-fms-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2200712
Dec 20, 2023 - Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
0
Reasons to Add Integer Holdings (ITGR) to Your Portfolio Now
https://www.zacks.com/stock/news/2200925/reasons-to-add-integer-holdings-itgr-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2200925
Dec 21, 2023 - Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
0
Here's Why You Should Retain Veeva Systems (VEEV) Stock Now
https://www.zacks.com/stock/news/2201457/here-s-why-you-should-retain-veeva-systems-veev-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2201457
Dec 22, 2023 - Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
0
Page 1>